ID   ZAP70_HUMAN             Reviewed;         619 AA.
AC   P43403; A6NFP4; Q6PIA4; Q8IXD6; Q9UBS6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   02-NOV-2010, entry version 133.
DE   RecName: Full=Tyrosine-protein kinase ZAP-70;
DE            EC=2.7.10.2;
DE   AltName: Full=70 kDa zeta-associated protein;
DE   AltName: Full=Syk-related tyrosine kinase;
GN   Name=ZAP70; Synonyms=SRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH
RP   CD3Z, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   MEDLINE=93046663; PubMed=1423621; DOI=10.1016/0092-8674(92)90598-7;
RA   Chan A.C., Iwashima M., Turck C.W., Weiss A.;
RT   "ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR
RT   zeta chain.";
RL   Cell 71:649-662(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Leukocyte;
RX   PubMed=14985102; DOI=10.1016/j.bbrc.2004.01.127;
RA   Kuroyama H., Ikeda T., Kasai M., Yamasaki S., Tatsumi M., Utsuyama M.,
RA   Saito T., Hirokawa K.;
RT   "Identification of a novel isoform of ZAP-70, truncated ZAP kinase.";
RL   Biochem. Biophys. Res. Commun. 315:935-941(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Blood, and Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 521-547, VARIANT STD LEU-GLU-GLN-541
RP   INS, AND FUNCTION.
RC   TISSUE=Lymphoid tissue;
RX   MEDLINE=94170394; PubMed=8124727; DOI=10.1016/0092-8674(94)90368-9;
RA   Arpaia E., Shahar M., Dadi H., Cohen A., Roifman C.M.;
RT   "Defective T cell receptor signaling and CD8+ thymic selection in
RT   humans lacking zap-70 kinase.";
RL   Cell 76:947-958(1994).
RN   [6]
RP   CHARACTERIZATION OF TAM-BINDING.
RX   MEDLINE=95105716; PubMed=7528772; DOI=10.1084/jem.181.1.375;
RA   Isakov N., Wange R.L., Burgess W.H., Watts J.D., Aebersold R.,
RA   Samelson L.E.;
RT   "ZAP-70 binding specificity to T cell receptor tyrosine-based
RT   activation motifs: the tandem SH2 domains of ZAP-70 bind distinct
RT   tyrosine-based activation motifs with varying affinity.";
RL   J. Exp. Med. 181:375-380(1995).
RN   [7]
RP   PHOSPHORYLATION AT TYR-315 AND TYR-319, AND MUTAGENESIS OF TYR-315 AND
RP   TYR-319.
RX   MEDLINE=99156907; PubMed=10037717; DOI=10.1074/jbc.274.10.6285;
RA   Di Bartolo V., Mege D., Germain V., Pelosi M., Dufour E., Michel F.,
RA   Magistrelli G., Isacchi A., Acuto O.;
RT   "Tyrosine 319, a newly identified phosphorylation site of ZAP-70,
RT   plays a critical role in T cell antigen receptor signaling.";
RL   J. Biol. Chem. 274:6285-6294(1999).
RN   [8]
RP   INTERACTION WITH CBL AND SLA.
RX   MEDLINE=99380595; PubMed=10449770; DOI=10.1073/pnas.96.17.9775;
RA   Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
RT   "SLAP, a dimeric adapter protein, plays a functional role in T cell
RT   receptor signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
RN   [9]
RP   INTERACTION WITH FCRL3.
RX   PubMed=11162587; DOI=10.1006/bbrc.2000.4213;
RA   Xu M.-J., Zhao R., Zhao Z.J.;
RT   "Molecular cloning and characterization of SPAP1, an inhibitory
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 280:768-775(2001).
RN   [10]
RP   INTERACTION WITH SHB.
RX   PubMed=12084069; DOI=10.1046/j.1432-1033.2002.03008.x;
RA   Lindholm C.K., Henriksson M.L., Hallberg B., Welsh M.;
RT   "Shb links SLP-76 and Vav with the CD3 complex in Jurkat T cells.";
RL   Eur. J. Biochem. 269:3279-3288(2002).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-292; TYR-315; TYR-319;
RP   TYR-492 AND TYR-493, AND MASS SPECTROMETRY.
RX   MEDLINE=22426906; PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-248; TYR-292; TYR-315;
RP   TYR-319; TYR-492 AND TYR-493, AND MASS SPECTROMETRY.
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-292; TYR-315; TYR-319;
RP   TYR-492 AND TYR-493, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=16094384; DOI=10.1038/nmeth776;
RA   Tao W.A., Wollscheid B., O'Brien R., Eng J.K., Li X.-J.,
RA   Bodenmiller B., Watts J.D., Hood L., Aebersold R.;
RT   "Quantitative phosphoproteome analysis using a dendrimer conjugation
RT   chemistry and tandem mass spectrometry.";
RL   Nat. Methods 2:591-598(2005).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-248; TYR-292 AND
RP   TYR-492, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-292 AND TYR-492, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-603, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-256.
RX   PubMed=12450381; DOI=10.1021/bi026465e;
RA   Folmer R.H., Geschwindner S., Xue Y.;
RT   "Crystal structure and NMR studies of the apo SH2 domains of ZAP-70:
RT   two bikes rather than a tandem.";
RL   Biochemistry 41:14176-14184(2002).
RN   [19]
RP   VARIANT STD ARG-518.
RX   MEDLINE=94261835; PubMed=8202713; DOI=10.1126/science.8202713;
RA   Chan A.C., Kadlecek T.A., Elder M.E., Filipovich A.H., Kuo W.-L.,
RA   Iwashima M., Parslow T.G., Weiss A.;
RT   "ZAP-70 deficiency in an autosomal recessive form of severe combined
RT   immunodeficiency.";
RL   Science 264:1599-1601(1994).
RN   [20]
RP   VARIANT STD HIS-465.
RX   MEDLINE=21306063; PubMed=11412303;
RX   DOI=10.1046/j.1365-2567.2001.01246.x;
RA   Toyabe S., Watanabe A., Harada W., Karasawa T., Uchiyama M.;
RT   "Specific immunoglobulin E responses in ZAP-70-deficient patients are
RT   mediated by Syk-dependent T-cell receptor signalling.";
RL   Immunology 103:164-171(2001).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-175; LEU-191; GLU-448 AND LEU-523.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Plays a role in T-cell development and lymphocyte
CC       activation. Essential for TCR-mediated IL-2 production. Isoform 1
CC       induces TCR-mediated signal transduction, isoform 2 does not.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts with SLA2 when it is phosphorylated. Interacts
CC       with CD3Z and with phosphorylated NFAM1. Interacts with CBLB (By
CC       similarity). Interacts with CBL and SLA when it is phosphorylated.
CC       The association with SLA (or SLA2) and CBL probably leads to its
CC       destruction. Interacts with SHB. Interacts with DEF6. Interacts
CC       (via SH2 domains) with RHOH (By similarity). Interacts with FCRL3.
CC   -!- INTERACTION:
CC       P06239:LCK; NbExp=1; IntAct=EBI-1211276, EBI-1348;
CC       Q9Y2R2:PTPN22; NbExp=2; IntAct=EBI-1211276, EBI-1211241;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Cell membrane (By
CC       similarity). Note=After antigen stimulation, isoform 1
CC       concentrates at the immunological synapse and isoform 2 remains
CC       cytoplasmic. Co-localizes together with RHOH in the immunological
CC       synapse. RHOH is required for its proper localization to the cell
CC       membrane and cytoskeleton fractions in the thymocytes (By
CC       similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P43403-1; Sequence=Displayed;
CC       Name=2; Synonyms=TZK;
CC         IsoId=P43403-2; Sequence=VSP_031156;
CC       Name=3;
CC         IsoId=P43403-3; Sequence=VSP_031157, VSP_031158;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed in T- and natural killer cells.
CC   -!- DOMAIN: The SH2 domains bind to the phosphorylated tyrosine-based
CC       activation motif (TAM) of CD3Z and the non-canonical
CC       phosphorylated tyrosine-based activation motif (TAM) of RHOH (By
CC       similarity).
CC   -!- PTM: Phosphorylated on tyrosine residues upon T-cell antigen
CC       receptor (TCR) stimulation. Tyr-319 phosphorylation is essential
CC       for full activity.
CC   -!- DISEASE: Defects in ZAP70 are the cause of selective T-cell defect
CC       (STD) [MIM:176947]. STD is an autosomal recessive form of severe
CC       combined immunodeficiency characterized by a selective absence of
CC       CD8-type T-cells.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SYK/ZAP-70 subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 2 SH2 domains.
CC   -!- WEB RESOURCE: Name=ZAP70base; Note=ZAP70 mutation db;
CC       URL="http://bioinf.uta.fi/ZAP70base/";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ZAP70";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L05148; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB083211; BAC43747.1; -; mRNA.
DR   EMBL; AC016699; AAX93187.1; -; Genomic_DNA.
DR   EMBL; BC039039; AAH39039.1; -; mRNA.
DR   EMBL; BC053878; AAH53878.1; -; mRNA.
DR   IPI; IPI00329789; -.
DR   IPI; IPI00410185; -.
DR   IPI; IPI00885038; -.
DR   PIR; A44266; A44266.
DR   PIR; A49955; A49955.
DR   RefSeq; NP_001070.2; -.
DR   RefSeq; NP_997402.1; -.
DR   UniGene; Hs.234569; -.
DR   PDB; 1M61; X-ray; 2.50 A; A=1-256.
DR   PDB; 1U59; X-ray; 2.30 A; A=327-606.
DR   PDB; 2OQ1; X-ray; 1.90 A; A=3-256.
DR   PDB; 2OZO; X-ray; 2.60 A; A=1-606.
DR   PDBsum; 1M61; -.
DR   PDBsum; 1U59; -.
DR   PDBsum; 2OQ1; -.
DR   PDBsum; 2OZO; -.
DR   ProteinModelPortal; P43403; -.
DR   IntAct; P43403; 7.
DR   MINT; MINT-110540; -.
DR   STRING; P43403; -.
DR   PhosphoSite; P43403; -.
DR   PRIDE; P43403; -.
DR   Ensembl; ENST00000264972; ENSP00000264972; ENSG00000115085.
DR   GeneID; 7535; -.
DR   KEGG; hsa:7535; -.
DR   UCSC; uc002syd.1; human.
DR   UCSC; uc002sye.1; human.
DR   CTD; 7535; -.
DR   GeneCards; GC02P098331; -.
DR   H-InvDB; HIX0002292; -.
DR   HGNC; HGNC:12858; ZAP70.
DR   HPA; CAB002625; -.
DR   HPA; HPA003134; -.
DR   MIM; 176947; gene+phenotype.
DR   Orphanet; 911; Combined immunodeficiency due to ZAP70 deficiency.
DR   PharmGKB; PA37447; -.
DR   eggNOG; prNOG17394; -.
DR   HOGENOM; HBG714705; -.
DR   HOVERGEN; HBG001540; -.
DR   InParanoid; P43403; -.
DR   OMA; FIEQGKR; -.
DR   OrthoDB; EOG908QT6; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; pi3kcipathway; Class I PI3K signaling events.
DR   Pathway_Interaction_DB; tcrpathway; TCR signaling in naive CD4+ T cells.
DR   Pathway_Interaction_DB; cd8tcrpathway; TCR signaling in naive CD8+ T cells.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   NextBio; 29481; -.
DR   PMAP-CutDB; P43403; -.
DR   ArrayExpress; P43403; -.
DR   Bgee; P43403; -.
DR   CleanEx; HS_ZAP70; -.
DR   Genevestigator; P43403; -.
DR   GermOnline; ENSG00000115085; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0042101; C:T cell receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0006955; P:immune response; IDA:UniProtKB.
DR   GO; GO:0007243; P:intracellular protein kinase cascade; NAS:UniProtKB.
DR   GO; GO:0045059; P:positive thymic T cell selection; IDA:MGI.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR012234; Tyr_kinase_non-rcpt_SYK/ZAP70.
DR   InterPro; IPR020686; Tyr_kinase_non-rcpt_ZAP-70.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 2.
DR   PANTHER; PTHR23256:SF98; Tyr_kinase_non-rcpt_ZAP-70; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 2.
DR   PIRSF; PIRSF000604; TyrPK_SYK; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm; Disease mutation; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Repeat;
KW   SCID; SH2 domain; Transferase; Tyrosine-protein kinase.
FT   CHAIN         1    619       Tyrosine-protein kinase ZAP-70.
FT                                /FTId=PRO_0000088168.
FT   DOMAIN       10    102       SH2 1.
FT   DOMAIN      163    254       SH2 2.
FT   DOMAIN      338    600       Protein kinase.
FT   NP_BIND     344    352       ATP (By similarity).
FT   ACT_SITE    461    461       Proton acceptor (By similarity).
FT   BINDING     369    369       ATP (By similarity).
FT   MOD_RES     248    248       Phosphotyrosine.
FT   MOD_RES     289    289       Phosphoserine.
FT   MOD_RES     292    292       Phosphotyrosine.
FT   MOD_RES     315    315       Phosphotyrosine.
FT   MOD_RES     319    319       Phosphotyrosine.
FT   MOD_RES     492    492       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     493    493       Phosphotyrosine.
FT   MOD_RES     603    603       N6-acetyllysine.
FT   VAR_SEQ       1    307       Missing (in isoform 2).
FT                                /FTId=VSP_031156.
FT   VAR_SEQ       1    126       Missing (in isoform 3).
FT                                /FTId=VSP_031157.
FT   VAR_SEQ     127    134       VRQTWKLE -> MRLGPRWK (in isoform 3).
FT                                /FTId=VSP_031158.
FT   VARIANT     175    175       R -> L (in dbSNP:rs55964305).
FT                                /FTId=VAR_041846.
FT   VARIANT     191    191       P -> L (in dbSNP:rs56403250).
FT                                /FTId=VAR_041847.
FT   VARIANT     448    448       G -> E (in a head and neck squamous cell
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041848.
FT   VARIANT     465    465       R -> H (in STD).
FT                                /FTId=VAR_015538.
FT   VARIANT     518    518       S -> R (in STD).
FT                                /FTId=VAR_006351.
FT   VARIANT     523    523       W -> L (in dbSNP:rs56189815).
FT                                /FTId=VAR_041849.
FT   VARIANT     541    541       K -> KLEQ (in STD).
FT                                /FTId=VAR_038688.
FT   MUTAGEN     315    315       Y->F: No inhibition of activation.
FT   MUTAGEN     319    319       Y->F: Inhibition of activation.
FT   TURN          4      7
FT   HELIX        17     26
FT   STRAND       34     38
FT   STRAND       40     42
FT   STRAND       46     52
FT   STRAND       55     63
FT   STRAND       69     71
FT   STRAND       77     79
FT   HELIX        80     89
FT   STRAND       94     96
FT   HELIX       114    131
FT   HELIX       135    156
FT   HELIX       157    160
FT   HELIX       170    178
FT   STRAND      186    191
FT   STRAND      197    204
FT   STRAND      207    215
FT   STRAND      221    223
FT   STRAND      229    231
FT   HELIX       232    241
FT   STRAND      246    248
FT   STRAND      316    320
FT   HELIX       334    336
FT   STRAND      337    345
FT   STRAND      350    357
FT   STRAND      364    371
FT   HELIX       377    392
FT   STRAND      401    415
FT   HELIX       422    426
FT   TURN        430    432
FT   HELIX       435    454
FT   HELIX       464    466
FT   STRAND      467    471
FT   STRAND      474    477
FT   HELIX       503    505
FT   HELIX       508    513
FT   HELIX       518    533
FT   TURN        539    542
FT   HELIX       546    553
FT   HELIX       566    574
FT   HELIX       580    582
FT   HELIX       586    601
SQ   SEQUENCE   619 AA;  69872 MW;  D1E1A8EC66FA116F CRC64;
     MPDPAAHLPF FYGSISRAEA EEHLKLAGMA DGLFLLRQCL RSLGGYVLSL VHDVRFHHFP
     IERQLNGTYA IAGGKAHCGP AELCEFYSRD PDGLPCNLRK PCNRPSGLEP QPGVFDCLRD
     AMVRDYVRQT WKLEGEALEQ AIISQAPQVE KLIATTAHER MPWYHSSLTR EEAERKLYSG
     AQTDGKFLLR PRKEQGTYAL SLIYGKTVYH YLISQDKAGK YCIPEGTKFD TLWQLVEYLK
     LKADGLIYCL KEACPNSSAS NASGAAAPTL PAHPSTLTHP QRRIDTLNSD GYTPEPARIT
     SPDKPRPMPM DTSVYESPYS DPEELKDKKL FLKRDNLLIA DIELGCGNFG SVRQGVYRMR
     KKQIDVAIKV LKQGTEKADT EEMMREAQIM HQLDNPYIVR LIGVCQAEAL MLVMEMAGGG
     PLHKFLVGKR EEIPVSNVAE LLHQVSMGMK YLEEKNFVHR DLAARNVLLV NRHYAKISDF
     GLSKALGADD SYYTARSAGK WPLKWYAPEC INFRKFSSRS DVWSYGVTMW EALSYGQKPY
     KKMKGPEVMA FIEQGKRMEC PPECPPELYA LMSDCWIYKW EDRPDFLTVE QRMRACYYSL
     ASKVEGPPGS TQKAEAACA
//
